Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMANC59)

Drug Name
AZD-3241 Drug Info
Synonyms Parkinson's disease therapeutic, AstraZeneca
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 2 [1]
Cross-matching ID
PubChem CID
11528958
CAS Number
CAS 890655-80-8
TTD Drug ID
DMANC59

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myeloperoxidase (MPO) TTVCZPI PERM_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Myeloperoxidase (MPO) DTT MPO 5.085 4.154 4.066 5.007
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Myeloperoxidase (MPO) DTT MPO 2.88E-01 -0.02 -0.16
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02388295) AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients. U.S. National Institutes of Health.
2 Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700.